Lancaster-based Simulations Plus entered a funded collaboration with an unnamed large pharmaceutical company that will enhance one of the company’s simulation software programs.
Biotechnology modeling and simulation software company Simulations Plus Inc. in Lancaster announced a funded collaboration with an unnamed animal health company.
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products sharewise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sharewise.com Daily Mail and Mail on Sunday newspapers.
Pharmaceutical simulation software company Simulations Plus announced the University+ program, which offers one year of free access to Simulations Plus programs for students and educators at accredited universities worldwide.
Simulations Plus Inc. received an order from China’s drug evaluation agency to license its GastroPlus product.
Financial terms of the deal between the Lancaster drug modeling software developer and the Center for Drug Evaluation of the National Medical Products Administration in China were not disclosed.
John DiBella, Simulations Plus division president said, the company has cultivated relationships with different institutions affiliated with China’s National Medical Products Administration to use its technology for the evaluation of drug specifications and bioequivalence.
“Now, researchers at the CDE will add GastroPlus to serve as a key platform for model-informed drug development to aid regulatory reviews,” DiBella said in a statement. “This news is welcomed by over 20 (and growing) domestic Chinese pharmaceutical companies and research hospitals that have been employing our technologies.”